Cepheid Licenses Quantovir's HPV IP to Develop Predictive Dx for Cervical Cancer

Sep 24, 2007

NEW YORK (GenomeWeb News) - Cepheid said today that it plans to use a family of human papillomavirus patents it has exclusively licensed from the Swedish company Quantovir to develop a PCR-based diagnostic test for HPV that will predict a woman’s risk for developing cervical cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

From a Clay Pipe to Sierra Leone

Researchers trace DNA on a clay pipe found at a former slave site to a population that lives in what is now Sierra Leone, the Washington Post reports.

Shawl Analysis

Two researchers report on their genetic analysis of samples from a shawl thought to belong to a victim of Jack the Ripper, ScienceInsider reports.

Japan to Issue Gene-Edited Food Rules

Japan is to release rules governing some gene-edited food, according to NHK World.

This Week in PLOS

In PLOS this week: computational strategy for improving gene set analysis testing, miRNAs linked to sleep apnea, and more.

Menu